TESARO (NASDAQ: TSRO) is one of 285 public companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its rivals? We will compare TESARO to similar companies based on the strength of its analyst recommendations, dividends, institutional ownership, profitability, valuation, earnings and risk.
This table compares TESARO and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
TESARO has a beta of 1.52, meaning that its stock price is 52% more volatile than the S&P 500. Comparatively, TESARO’s rivals have a beta of 1.63, meaning that their average stock price is 63% more volatile than the S&P 500.
Institutional & Insider Ownership
50.3% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 34.6% of TESARO shares are owned by insiders. Comparatively, 16.6% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
This is a breakdown of recent ratings and target prices for TESARO and its rivals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
TESARO presently has a consensus price target of $158.57, indicating a potential upside of 83.44%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 44.20%. Given TESARO’s higher probable upside, equities analysts plainly believe TESARO is more favorable than its rivals.
Earnings and Valuation
This table compares TESARO and its rivals top-line revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|TESARO||$44.82 million||-$387.47 million||-10.25|
|TESARO Competitors||$284.30 million||$34.29 million||135.48|
TESARO’s rivals have higher revenue and earnings than TESARO. TESARO is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
TESARO rivals beat TESARO on 8 of the 12 factors compared.
TESARO, Inc. is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform. Rolapitant is a potent and long-acting neurokinin-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting. Niraparib is an orally active and potent poly (adenosine diphosphate (ADP)-ribose) polymerase inhibitor. It has various ongoing clinical trials evaluating niraparib for the treatment of ovarian or breast cancers. It has initiated a Phase I, dose escalation study for its first immuno-oncology antibody, TSR-042, which targets Programmed cell death protein 1. It has commenced pre-clinical research for its antibody candidate targeting Lymphocyte-activation gene-3 andTSR-033. It has commenced a Phase I clinical trial of TSR-042.
What are top analysts saying about TESARO Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for TESARO Inc and related companies.